Aileron Therapeutics Inc., of Watertown, Mass., said it closed its underwritten public offering of common stock, including the exercise by the underwriter of the option to purchase an additional 1.07 million shares at $1.10 each. The total number of shares sold amounted to 10.16 million shares for gross proceeds of $11.2 million. The company expects to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to fund clinical development of ALRN-6924 as a chemoprotective agent and for working capital as well as other general corporate purposes.
Amyris Inc., of Emeryville, Calif., said it closed its private investment in public equity and received total gross proceeds of $200 million. The company expects to use the proceeds for general corporate purposes and to repay certain outstanding indebtedness.
Antibe Therapeutics Inc., of Toronto, said it entered a bought deal agreement with a syndicate of underwriters who will purchase 62.5 million units at CA40 cents each for gross proceeds of CA$25 million (US$18.67 million). Each unit consists of one common share and one-third of one common share purchase warrant. Each whole warrant is exercisable for one common share at CA60 cents per share. In addition, the underwriters will have the option to acquire up to that number of additional units equal to 15% of the units sold and/or additional warrants equal to 15% of the number of warrants sold. If the overallotment option is exercised in full, the total gross proceeds would be CA$28.75 million. The net proceeds will be used to fund activities required for large market partnering and in support of the phase III program for ATB-346, for business development activities, and for advancing the other drugs in the company’s pipeline. The remainder will be used for working capital and general corporate purposes.
Appili Therapeutics Inc., of Halifax, Nova Scotia, said it closed its public offering, issuing a total of 12.93 million units at $1.20 each for gross proceeds of CA$15.525 million (US$11.59 million), which includes the exercise in full by the agents of their overallotment option to purchase 1.687 million additional units for additional gross proceeds of CA$2.025 million. The company also closed a nonbrokered private placement of 1.2 million units for gross proceeds of CA$1.44 million. The net proceeds will be used primarily toward funding planned research and development activities for the clinical trial evaluating Fujifilm Toyama Chemical Inc.’s drug, favipiravir, in long-term care facilities as a potential preventive measure against COVID-19. Funds will also be used to cover development costs for other product candidates, as well as for working capital and general corporate purposes.
Applied Molecular Transport Inc., of South San Francisco, said it closed its IPO of 12.65 million shares, which includes the exercise in full by the underwriters of their option to purchase up to 1.65 million additional shares, at a public offering price of $14 each. The total gross proceeds were $177.1 million.
Can-Fite Biopharma Ltd., of Petach Tikva, Israel, signed definitive agreements with several institutional and accredited investors for the purchase and sale of about 3.9 million American depositary shares (ADSs), at a purchase price of $2.05 per ADS, in a registered direct offering. Can-Fite has also agreed to issue and sell to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of about 1.9 million ADSs. Each represents 30 ordinary shares. The offering is expected to close on or about June 12. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Shares of Can-Fite (NYSE American:CANF) fell 44 cents, or 19.7%, to close June 10 at $1.82.
Fulcrum Therapeutics Inc., of Cambridge, Mass., closed a $68.5 million private placement, pursuant to a securities purchase agreement with a group of institutional investors. The deal includes a mix of new and existing investors, including Ecor1 Capital LLC, Alyeska Investment Group LP, Boxer Capital, Casdin Capital LLC, Perceptive Advisors LLC, Samsara Biocapital, Monashee Investment Management LLC and Foresite Capital. SVB Leerink acted as the exclusive placement agent to the company. Sold were about 4 million shares at $17. The transaction priced June 8. The company expects to use net proceeds from the private placement to fund research and development expenses.
Immunic Inc., of New York, priced its public offering of about 2.1 million shares at $11.40 each, for gross proceeds of about $25 million. The offering is expected to close on or about June 12. Roth Capital Partners and Ladenburg Thalmann acted as placement agents. Shares of Immunic (NASDAQ:IMUX) fell 91 cents to close June 10 at $11.89.
Innocan Pharma Corp., of Toronto, said it closed its marketed short form prospectus offering in which it issued 28.4 million units at a price of CA18 cents per unit for gross proceeds of $5.1 million (US$3.8 million). The offering was led by Mackie Research Capital Corp., as sole bookrunner, and Canaccord Genuity Corp. as co-lead agents, together with Haywood Securities Inc. and PI Financial Corp. Net proceeds will be used for research and product development expenses, sales and marketing expenses, operating expenses and general and administrative expenses as well as for working capital and general corporate purposes. Tamar Innovest Ltd., the company's largest shareholder, and a company managed by Ralph Bossino, a director of the company, purchased 3.9 million units for an aggregate purchase price of CA$700,000. Tamar now owns or exercises control or direction of 34.4 million common shares, representing about 19.6% of the total issued and outstanding shares of the offering following closing.
Legend Biotech Corp., of Somerset, N.J., closed its IPO of about 21 million American depositary shares (ADSs), each representing two ordinary shares, at a public offering price of $23 per ADS, for total gross proceeds of about $487.3 million. The number of ADSs issued at closing included the exercise in full of the underwriters’ option to purchase about 2.7 million additional ADSs. Morgan Stanley, J.P. Morgan and Jefferies acted as joint book-running managers.
Oncology Venture A/S, of Horsholm, Denmark, said it will issue about 2.2 million shares at a price per share of SEK1.33 (US14 cents)to Negma Group Ltd. The share issue is carried out pursuant to the convertible note agreement with Negma Group Ltd. and Park Partners GB. Oncology Venture said on April 3 that it has called upon the first tranche of convertible notes of SEK10 million, in line with the terms from the financing agreement communicated on March 31. Negma has requested to convert SEK3 million of the notes into about 2.2 million shares of nominal DKK0.05 (US$ 0.007) each.
Vedanta Biosciences Inc., of Cambridge, Mass. received $12 million in additional capital and R&D collaboration funds from new and existing investors, including JSR Corp., bringing the company’s total series C/C-2 funding to $71.1 million.